QT Prolongation Risk Calculator
Patient Risk Assessment
This tool helps identify patients at high risk for QT prolongation when prescribed macrolide antibiotics. Based on AHA guidelines and clinical studies, it assesses seven key risk factors.
Risk Assessment
Your patient's QT prolongation risk score:
Recommendations:
Macrolides are among the most commonly prescribed antibiotics in the U.S., used for everything from sinus infections to pneumonia. But for some patients, these drugs carry a hidden danger: a rare but deadly heart rhythm problem called Torsades de Pointes. It’s not common-but when it happens, it can be fatal. The risk isn’t the same for all macrolides, and it’s not the same for all patients. Knowing who’s at risk and why can save lives.
How Macrolides Affect the Heart
Macrolide antibiotics like azithromycin, clarithromycin, and erythromycin work by stopping bacteria from making proteins. But they also interact with a specific ion channel in heart cells called IKr, which controls how quickly the heart resets after each beat. When this channel gets blocked, the heart takes longer to repolarize. On an ECG, that shows up as a longer QT interval.
That delay might sound harmless, but it can trigger early afterdepolarizations-abnormal electrical spikes that set off chaotic heart rhythms. The most dangerous of these is Torsades de Pointes, a twisting pattern of ventricular tachycardia that can degenerate into cardiac arrest. It doesn’t happen often, but when it does, it often happens fast.
Research shows clarithromycin is the strongest blocker of IKr, followed by erythromycin. Azithromycin is weaker, but it’s still a player. A 2023 study in Frontiers in Cardiovascular Medicine confirmed this ranking: clarithromycin ≈ roxithromycin > erythromycin > azithromycin. That’s why clarithromycin shows up more often in adverse event reports-even though it’s prescribed less often.
The Real Risk: It’s Not the Drug, It’s the Patient
Most people who take azithromycin for a sore throat won’t have a problem. The baseline risk of TdP in healthy adults is less than 1 in 100,000. But add just one risk factor, and that number climbs.
The American Heart Association lists seven major risk factors:
- Female sex (2-3.5 times higher risk)
- Age over 65 (1.8 times higher risk)
- Structural heart disease (2.2 times higher risk)
- Low potassium or magnesium (3.1 times higher risk)
- Concurrent use of other QT-prolonging drugs (2.5-5 times higher risk)
- Kidney impairment (1.7 times higher risk)
- Genetic long QT syndrome (5-10 times higher risk)
Here’s the catch: most patients who end up with TdP have at least two of these. A 2021 case series in the Journal of Clinical Medicine found that 9 out of 12 patients with clarithromycin-induced TdP were taking another QT-prolonging drug-often a diuretic, antidepressant, or antifungal. Nearly all had low potassium. That’s not coincidence. That’s a perfect storm.
Comparing Macrolides: Clarithromycin vs. Azithromycin
There’s a lot of confusion around whether azithromycin is safer than clarithromycin. The answer is yes-but not by much, and only in low-risk people.
A 2012 study in the New England Journal of Medicine by Wayne Ray and colleagues found azithromycin was linked to a 2.88 times higher risk of cardiovascular death compared to amoxicillin. That caused a major stir. But later studies dug deeper. When researchers adjusted for 108 variables-including why the patient was prescribed the antibiotic in the first place-the difference vanished. The odds ratio dropped to 1.01. That suggests the real issue isn’t azithromycin itself, but that sicker patients get it more often.
Clarithromycin, on the other hand, consistently shows higher risk. A 2012 Danish study found clarithromycin was tied to a 77% higher risk of cardiac death than penicillin V. The FDA’s own adverse event database from 2010-2020 showed clarithromycin accounted for 58% of all macrolide-related QT events, even though it’s only used in about 15% of cases.
Why? Three reasons:
- It’s a stronger IKr blocker.
- It inhibits CYP3A4, which means it can raise levels of other QT-prolonging drugs (like statins or antiarrhythmics).
- It’s often prescribed to older patients with multiple meds and kidney issues.
Azithromycin doesn’t inhibit CYP3A4, so it’s less likely to cause drug interactions. But it still prolongs QT-just less. And when combined with other risk factors, even a small prolongation can be dangerous.
What About Other Antibiotics?
Not all antibiotics carry this risk. Doxycycline, amoxicillin, and cephalexin have no known QT effect. Fluoroquinolones like levofloxacin and moxifloxacin do-sometimes more than macrolides. Moxifloxacin can prolong QT by 15-20 ms, similar to clarithromycin.
But here’s the problem: doctors often pick macrolides because they’re good for atypical pneumonia, bronchitis, and sinus infections. They’re also less likely to cause diarrhea than fluoroquinolones. So even when the risk is known, there’s still a reason to use them.
The key isn’t avoiding macrolides entirely-it’s avoiding them in the wrong people.
How to Stay Safe: A Practical Guide
Doctors aren’t supposed to guess. There are tools to help.
The AHA recommends a three-step approach:
- Screen for the seven risk factors before prescribing. Check the ECG for baseline QTc. Men >450 ms, women >470 ms = high risk.
- Check electrolytes. Low potassium or magnesium? Fix them first. Don’t just assume they’re fine.
- Look at the full med list. Is the patient on a diuretic? An SSRI? A calcium channel blocker? A Class Ia or III antiarrhythmic? Each one adds up.
For patients with two or more risk factors, consider alternatives. If you’re treating community-acquired pneumonia, doxycycline or a cephalosporin might be just as effective.
There’s also a simple scoring tool-the QT Risk Score from the University of Arizona. It assigns points for each risk factor. A score of 7 or higher means high risk. Avoid macrolides entirely in those cases.
Real-World Impact: What Hospitals Are Doing
Some health systems have already acted. Kaiser Permanente, which serves over 12 million people, added a pop-up alert in their EHR system in 2017. If a doctor tried to prescribe azithromycin or clarithromycin to a patient with a QTc >500 ms or on three or more QT-prolonging drugs, the system blocked the prescription unless overridden. Result? A 28% drop in high-risk prescriptions.
Meanwhile, clarithromycin use in cardiac patients has dropped 34% since 2013. Azithromycin use hasn’t changed much-partly because many still believe it’s safer. But that belief is outdated.
The Future: Safer Antibiotics?
Solithromycin, a newer ketolide, showed no QT prolongation in clinical trials. It was designed to avoid the IKr blockade that causes the problem. But the FDA rejected it in 2016 because of liver toxicity. That’s the trade-off: fix one safety issue, and another pops up.
Right now, there’s no magic bullet. The best tool we have is awareness. And careful prescribing.
What Patients Should Know
If you’re prescribed a macrolide and you have heart disease, take diuretics, or are over 65, ask: "Is there another antibiotic I could take?" Don’t assume azithromycin is "safe." It’s safer than clarithromycin-but not risk-free.
Also, if you’re on multiple medications, bring your full list to your doctor. Many QT-prolonging drugs are common: antidepressants, antifungals, anti-nausea meds, even some heartburn pills. They add up.
If you feel dizzy, lightheaded, or have palpitations after starting the antibiotic, stop it and call your doctor. Don’t wait. TdP can strike quickly.
Do all macrolides carry the same risk of arrhythmia?
No. Clarithromycin has the highest risk, followed by erythromycin. Azithromycin carries a lower but still present risk. Clarithromycin is a stronger blocker of the IKr potassium channel and also interferes with liver enzymes that break down other QT-prolonging drugs. Azithromycin doesn’t affect those enzymes, which is why it’s often chosen over the others-but it still prolongs the QT interval, especially in high-risk patients.
Can azithromycin cause sudden cardiac death?
Yes, but it’s rare. The absolute risk is very low in healthy people. However, in patients with multiple risk factors-like older age, heart disease, low potassium, or taking other QT-prolonging drugs-the risk increases significantly. A 2012 study found 152 excess cardiovascular deaths per million courses of azithromycin. That’s not common, but it’s preventable with better screening.
Should I get an ECG before taking a macrolide?
If you have any of the seven major risk factors (female sex, age over 65, heart disease, low potassium, kidney problems, genetic long QT, or taking other QT-prolonging drugs), yes. A baseline ECG to check your QTc interval is simple, cheap, and can prevent a life-threatening event. For healthy young adults with no other meds or conditions, it’s usually not needed.
Are there safer antibiotics for people with heart conditions?
Yes. For many infections, doxycycline, amoxicillin, or cephalexin are just as effective and carry no known QT risk. Fluoroquinolones like levofloxacin also prolong QT, so they’re not always safer. The best choice depends on the infection type and patient history. Always ask your doctor if there’s a non-QT-prolonging alternative.
Why is clarithromycin more dangerous than azithromycin?
Clarithromycin blocks the IKr potassium channel more strongly than azithromycin, leading to greater QT prolongation. It also inhibits the CYP3A4 enzyme, which can raise levels of other QT-prolonging drugs like statins or antiarrhythmics. Azithromycin doesn’t inhibit this enzyme, so it has fewer dangerous interactions. But both can still cause arrhythmias in high-risk patients.
How common is Torsades de Pointes from macrolides?
The estimated incidence is 3-7 cases per million treatment courses. In the U.S., the FDA’s adverse event database recorded 287 cases of TdP linked to macrolides between 2010 and 2020. Most occurred in patients with multiple risk factors. While rare, these events are often fatal-making prevention critical.
matthew runcie
March 21, 2026 AT 01:35Man, I’ve been on azithromycin like 3 times and never thought twice about it. Guess I got lucky. But reading this makes me wonder how many people just brush off dizziness as "just the flu" when it’s actually their heart going sideways.
Timothy Olcott
March 22, 2026 AT 00:52Y’all actin like this is some new revelation 😂 I’ve been tellin’ my nurse at the VA for years: "Don’t give Clarithro to Grandpa on 7 meds." She just sighed and said "protocol." 🤷♂️💉 #MedSystemFail
Nishan Basnet
March 23, 2026 AT 05:35This is one of those rare posts that actually bridges clinical science and real-world practice. The way the author broke down the risk factors-not just listing them but showing how they compound-is textbook-level clarity. I’ve seen patients on fluoxetine + furosemide + azithromycin and wondered how anyone approved it. The fact that EHR alerts are reducing high-risk prescriptions by 28%? That’s the kind of systemic change we need more of.
Also, the point about azithromycin being "safer" is misleading. It’s not safer-it’s *less dangerous* in isolation. But in polypharmacy? It still contributes to the storm. We need better patient education, not just provider guidelines.
Allison Priole
March 24, 2026 AT 13:30I’m a nurse and I used to think azithromycin was the "safe" macrolide until I had a 72-year-old patient go into TdP after a Z-pack. She was on lisinopril, hydrochlorothiazide, and sertraline. We didn’t check her K+ because she "always had normal labs." She didn’t have a history of heart issues. She was just… old. And tired. And on too many meds. I’ll never forget how her ECG looked when it twisted. It wasn’t scary because it was rare-it was scary because it was so preventable.
Also, why do we still call it "Z-pack" like it’s a snack? We need to stop making antibiotics sound like they’re harmless. They’re not.
Casey Tenney
March 25, 2026 AT 07:58If you’re over 65 and on meds, don’t take any macrolide. Period. No exceptions. This isn’t a "risk"-it’s a death sentence waiting for a prescription.
Jackie Tucker
March 26, 2026 AT 19:56Oh wow, a 2012 NEJM study "proved" azithromycin was dangerous… until they adjusted for 108 variables. How convenient. Clearly, Big Pharma just needed someone to "adjust" the data until the numbers looked right. Next you’ll tell me the moon landing was fake.
And why is no one talking about how the FDA blocked solithromycin over liver toxicity? Sounds like they’d rather let people die of pneumonia than risk a slightly toxic drug. Classic.
Thomas Jensen
March 27, 2026 AT 16:53Wait… so you’re telling me the government and Big Pharma are hiding this? I’ve been on clarithromycin twice. My dad died of "sudden cardiac arrest" at 68. He was on Lipitor and a diuretic. Coincidence? I think not. They don’t want you to know this. They profit off the chaos. Read the fine print. Read the adverse event reports. The numbers are there. They just don’t want you to connect the dots.
Solomon Kindie
March 27, 2026 AT 22:08So we’re saying the real problem is not the drug but the patient? That’s just victim blaming with a lab coat. If the system is designed to pump out prescriptions without screening, then the system is broken. We don’t need more warnings-we need mandatory ECGs before any QT drug is prescribed. Simple. Clean. Done.
Also, why is no one mentioning that fluoroquinolones are worse? Because they’re cheaper? Or because they’re used for UTIs and no one cares about old ladies peeing?
Natali Shevchenko
March 28, 2026 AT 06:05I’ve been thinking about this a lot since my mom was prescribed azithromycin after a sinus infection last year. She’s 71, on a beta-blocker, has mild CKD, and her potassium was borderline low. The doctor didn’t check anything. I asked. They said "it’s fine." I looked up the QT Risk Score myself and she scored a 9. I refused to let her fill it. We switched to doxycycline. She’s fine. But how many people don’t have someone like me to advocate for them? This isn’t about medical knowledge-it’s about access, power, and who gets listened to. The system fails the most vulnerable every day. This post is important because it’s not theoretical. It’s personal.
Nicole James
March 28, 2026 AT 09:38And yet… we still prescribe macrolides like candy. Why? Because they’re cheap. Because they’re "broad-spectrum." Because the patient wants something "strong." But we don’t tell them the truth: that this isn’t a cure-it’s a gamble. And the house always wins. The FDA knows. The AMA knows. The hospitals know. But they keep writing the script. Because changing the script means admitting they’ve been killing people quietly for decades.
And now… we have a pop-up alert. A tiny, digital, bureaucratic Band-Aid. It’s not enough. It’s never enough. The real question isn’t whether azithromycin is dangerous… it’s why we let ourselves believe it’s not.